Keymed Biosciences Co.ltd

This study tested a new drug called CM310 in 180 teenagers with moderate-to-severe atopic dermatitis (eczema). The drug is a lab-made antibody that blocks a key protein involved in inflammation. The goal was to see if it improves skin clearing and reduces itch compared to a place…

This early-stage trial tests a new drug called CM512 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the body handles the drug. 110 participants will receive either CM512 or a placebo, and researchers w…

This Phase 3 trial tests whether Stapokibart injection can reduce severe itching and skin bumps in adults with prurigo nodularis. About 200 participants will receive either the drug or a placebo for 24 weeks. The main goal is to see if itching improves by at least 4 points on a 0…